Abstract
In the last twenty years, numerous reports provided solid evidence on the involvement of the mitochondrial permeability transition pore (PTP) in myocardial injury caused by ischemia and reperfusion. Indeed, significant cardioprotection is obtained by reducing the open probability of the PTP. This goal has been achieved by pharmacological and genetic interventions aimed at inhibiting cyclophilin D (CyPD), a regulatory protein that favors PTP opening. On the other hand, CyPD inhibition or deletion has been shown to worsen remodeling of the hypertrophic heart, an adverse outcome that must find an explanation within PTP modulation by CyPD. In this review, recent advancements in defining the molecular identity of the PTP are analyzed in relation to its pathophysiological functions and pharmacological modulation. In this respect, advantages and limitations of compounds targeting CyPD are discussed with the analysis of novel PTP inhibitors that do not interact with CyPD.
Keywords: Permeability transition, cyclophilin D, reactive oxygen species, calcium, ischemia, heart.
Current Medicinal Chemistry
Title:Modulation of Mitochondrial Permeability Transition in Ischemia-Reperfusion Injury of the Heart. Advantages and Limitations
Volume: 22 Issue: 20
Author(s): Fabio Di Lisa and Paolo Bernardi
Affiliation:
Keywords: Permeability transition, cyclophilin D, reactive oxygen species, calcium, ischemia, heart.
Abstract: In the last twenty years, numerous reports provided solid evidence on the involvement of the mitochondrial permeability transition pore (PTP) in myocardial injury caused by ischemia and reperfusion. Indeed, significant cardioprotection is obtained by reducing the open probability of the PTP. This goal has been achieved by pharmacological and genetic interventions aimed at inhibiting cyclophilin D (CyPD), a regulatory protein that favors PTP opening. On the other hand, CyPD inhibition or deletion has been shown to worsen remodeling of the hypertrophic heart, an adverse outcome that must find an explanation within PTP modulation by CyPD. In this review, recent advancements in defining the molecular identity of the PTP are analyzed in relation to its pathophysiological functions and pharmacological modulation. In this respect, advantages and limitations of compounds targeting CyPD are discussed with the analysis of novel PTP inhibitors that do not interact with CyPD.
Export Options
About this article
Cite this article as:
Lisa Di Fabio and Bernardi Paolo, Modulation of Mitochondrial Permeability Transition in Ischemia-Reperfusion Injury of the Heart. Advantages and Limitations, Current Medicinal Chemistry 2015; 22 (20) . https://dx.doi.org/10.2174/0929867322666150530210005
DOI https://dx.doi.org/10.2174/0929867322666150530210005 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Angiogenesis-regulating microRNAs and Ischemic Stroke
Current Vascular Pharmacology Anabolic Androgenic Steroid (AAS) Related Deaths: Autoptic, Histopathological and Toxicological Findings
Current Neuropharmacology Mitochondriotropic Cationic Vesicles A Strategy Towards Mitochondrial Gene Therapy
Current Pharmaceutical Biotechnology Role of Redox Homeostasis and Inflammation in the Pathogenesis of Pulmonary Arterial Hypertension
Current Medicinal Chemistry Role of Platelet Function Testing in Clinical Practice: Current Concepts and Future Perspectives
Current Drug Targets Role of Reactive Oxygen Species in Tumor Necrosis Factor-alpha Induced Endothelial Dysfunction
Current Hypertension Reviews Potential of Sulphur-containing Amino Acids in the Prevention of Catecholamine-induced Arrhythmias
Current Medicinal Chemistry Cell-Permeable Peptide Inhibitor of c-Jun NH2-Terminal Kinase for the Treatment of Diabetes
Current Bioactive Compounds Iron Involvement in Multiple Signaling Pathways of Atherosclerosis: A Revisited Hypothesis
Current Medicinal Chemistry Thiazolidinediones and Cardiovascular Risk — A Question of Balance
Current Cardiology Reviews Up-Regulation of TLR-4 in the Brain After Ischemic Kidney-Induced Encephalopathy in the Rat
CNS & Neurological Disorders - Drug Targets The Role of Chemokines, Cytokines and Adhesion Molecules in Stem Cell Trafficking and Homing
Current Pharmaceutical Design Actual Knowledge of Systemic Inflammation Reaction During Cardiopulmonary Bypass
Recent Patents on Cardiovascular Drug Discovery Proteinase-Activated Receptor 2 (PAR2): A Challenging New Target for Treatment of Vascular Diseases
Current Pharmaceutical Design Neuregulin1 as Novel Therapy for Heart Failure
Current Pharmaceutical Design Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Subject Index to Volume 10
Current Pharmaceutical Design Pharmacological Inhibition of Poly(ADP-ribose) Polymerase in Cardiovascular Disorders: Future Directions
Current Vascular Pharmacology Na+/Ca2+ Exchange Inhibitors: A New Class of Calcium Regulators
Cardiovascular & Hematological Disorders-Drug Targets S-nitrosation/Denitrosation in Cardiovascular Pathologies: Facts and Concepts for the Rational Design of S-nitrosothiols
Current Pharmaceutical Design